News | February 07, 2023
Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Subscribe To Our Newsletter & Stay Updated
